RxDoctor Payments Data

Susan Balmer, MD

Internal Medicine · Marquette, MINPI 1164640058

Payments from drug & device makers

$2,708in general payments, 2019–2025

Across 166 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$659
  • Amgen$587
  • Novartis$199
  • Merck$178
  • Bayer$162
  • Lilly USA, LLC$151
  • plus $772 from 18 others

What the payments were for

  • Food & beverage$2,67999%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,708 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$132,041
Medicare patients
268
Services billed
3,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban225$249,223
XareltoRivaroxaban115$129,046
JardianceEmpagliflozin98$91,150
OzempicSemaglutide34$80,509
TrulicityDulaglutide44$72,483
FarxigaDapagliflozin Propanediol57$70,240
RybelsusSemaglutide41$62,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$49,086
MounjaroTirzepatide30$32,453
Spiriva RespimatTiotropium Bromide38$30,339
EntrestoSacubitril/Valsartan19$21,355
Synjardy XrEmpagliflozin/Metformin Hcl15$19,976
UbrelvyUbrogepant12$16,376
LinzessLinaclotide15$16,363
MyrbetriqMirabegron18$14,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$28$253,176236 claims
Novo NordiskOzempic, Rybelsus$74$143,17775 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr$116$141,465151 claims
Johnson & JohnsonXarelto$46$129,046115 claims
Lilly USA, LLCTrulicity, Mounjaro$151$104,93674 claims
AstraZenecaFarxiga, Symbicort$85$74,20273 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$43$65,36270 claims
AbbVieUbrelvy, Linzess$659$32,73927 claims
NovartisEntresto$199$21,35519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Marquette

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →